Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors.

@article{Pertwee1998PharmacologicalPA,
  title={Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors.},
  author={R. G. Pertwee},
  journal={Biochemical Society transactions},
  year={1998},
  volume={26 2},
  pages={
          267-72
        }
}
  • R. Pertwee
  • Published 1998
  • Chemistry, Medicine
  • Biochemical Society transactions
It is now generally accepted that many of the known pharmacological effects of cannabinoids are mediated by receptors. These are CBI, that are expressed mainly by central and peripheral neurons, and CBz, that occur mainly in immune cells [1,2]. The discovery of these receptors has prompted the development of selective CB, and CBz receptor agonists and antagonists [ 1 , 3 4 1 and has also led to the demonstration that there are endogenous agonists for these receptors in mammalian tissues [ 1,2… Expand
Cannabinoid Receptors and Their Ligands in Brain and Other Tissues
TLDR
The discovery of the endogenous cannabinoid system has important physiological, pathophysiological, pharmacological, and therapeutic implications, and one possible therapeutic strategy for the future is the development and use of drugs that activate cannabinoid receptors indirectly by modulating extracellular levels of endogenous cannabinoids. Expand
From cannabis to cannabinergics: new therapeutic opportunities.
TLDR
A reuptake system for the transport of anandamide across the cell membrane is characterized, and it is shown that selective inhibition of this transporter is associated with analgesia and peripheral vasodilation. Expand
Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development
  • R. Pertwee
  • Chemistry, Medicine
  • Expert opinion on investigational drugs
  • 2000
This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools orExpand
Cannabis and cannabinoid receptors.
TLDR
With the discovery of cannabinoid receptors for exogenous cannabinoids, also endogenous cannabinoids (anandamide, 2-arachidonylglycerol) have been described. Expand
Pharmacological and therapeutic targets for Δ9 tetrahydrocannabinol and cannabidiol
SummaryCannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of Δ9-tetrahydrocannabinol (Δ9-THC), the mainExpand
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
We have previously developed quinolone-3-carboxamides with the aim of obtaining new ligands for both cannabinoid receptors, CB1 and CB2. Our preliminary screening led to the identification ofExpand
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPγS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide
TLDR
The prolonged exposure of rats to R-methanandamide, a more stable analog of anandamide), was able to produce cannabinoid receptor-related changes in contrast with the absence of changes observed early with the metabolically labile an andamide. Expand
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
TLDR
The manipulation of the endocannabinoid signaling might serve to treat cannabis addiction and, in particular, the addiction to other drugs such as alcohol, nicotine or opioids. Expand
Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
TLDR
Findings demonstrate marked differences among cannabinoid receptor agonists in their activation of intracellular transduction pathways, providing support for the emerging concept of agonist-specific trafficking of cellular responses and further suggests strategies for developing receptors agonists with increased therapeutic utility. Expand
The Endogenous Cannabinoid, Anandamide, Activates the Hypothalamo-Pituitary-Adrenal Axis in CB1 Cannabinoid Receptor Knockout Mice
TLDR
The results strongly support the view that activation of the HPA axis produced by AEA possibly occurs via a currently unknown (CBx) cannabinoid receptor present in PVN. Expand
...
1
2
3
4
5
...

References

Academic Press, London 33 Consroe, P. and Sandyk, R. (1992) in Marijuana/ Cannabinoids: Neurobiology and Neurophysiology (Murphy, L
  • 1992